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Abstract
Background: Dysregulation of the human Transforming Acidic Coiled Coil (TACC) genes is thought to be
important in the development and progression of multiple myeloma, breast and gastric cancer. Recent, large-scale
genomic analysis and Serial Analysis of Gene Expression data suggest that TACC1 and TACC3 may also be
involved in the etiology of ovarian tumors from both familial and sporadic cases. Therefore, the aim of this study
was to determine the occurrence of alterations of these TACCs in ovarian cancer.
Methods: Detection and scoring of TACC1 and TACC3 expression was performed by immunohistochemical
analysis of the T-BO-1 tissue/tumor microarray slide from the Cooperative Human Tissue Network, Tissue Array
Research Program (TARP) of the National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Tumors were categorized as either positive (greater than 10% of cells staining) or negative. Statistical analysis was
performed using Fisher's exact test and p < 0.05 (single comparisons), and p < 0.02 (multiple comparisons) were
considered to be significant. Transgenomics WAVE high performance liquid chromatography (dHPLC) was used
to pre-screen the TACC3 gene in constitutional DNA from ovarian cancer patients and their unaffected relatives
from 76 families from the Gilda Radner Familial Ovarian Cancer Registry. All variant patterns were then
sequenced.
Results: This study demonstrated absence of at least one or both TACC proteins in 78.5% (51/65) of ovarian
tumors tested, with TACC3 loss observed in 67.7% of tumors. The distribution pattern of expression of the two
TACC proteins was different, with TACC3 loss being more common in serous papillary carcinoma compared
with clear cell carcinomas, while TACC1 staining was less frequent in endometroid than in serous papillary tumor
cores. In addition, we identified two constitutional mutations in the TACC3 gene in patients with ovarian cancer
from the Gilda Radner Familial Ovarian Cancer Registry. These patients had previously tested negative for
mutations in known ovarian cancer predisposing genes.
Conclusion: When combined, our data suggest that aberrations of TACC genes, and TACC3 in particular,
underlie a significant proportion of ovarian cancers. Thus, TACC3 could be a hitherto unknown endogenous
factor that contributes to ovarian tumorigenesis.
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Background
It is apparent that for a normal cell to develop into a
highly delocalized metastatic cancer, multiple genetic
events are required to overcome the normal mechanisms
that control the growth and development of healthy tis-
sue. About 10% of ovarian cancer patients inherit a famil-
ial predisposition, and of those cases, only 35–50% can
be attributed to the inheritance of defects in the BRCA1
and BRCA2 tumor suppressor genes [1,2]. In addition,
BRCA1 and BRCA2 mutations are not directly involved in
the initiation events leading to the development of spo-
radic tumors, indicating that additional, as yet unidenti-
fied genes must play a significant role in the etiology of
both familial and sporadic ovarian cancer. In ovarian can-
cer, comparative genomic hybridization (CGH), multi-
color spectral karyotyping (SKY), and loss of
heterozygosity (LOH) studies have identified several
regions of the genome that may contain novel genes
involved in the development and progression of ovarian
cancer [3-5]. These techniques have indicated that dele-
tions or rearrangements of 4p16 and 8p11, the loci for
TACC3 and TACC1 respectively, commonly occur in 40%
of ovarian cancer cell lines and primary tumors from both
familial and sporadic cases [3-5]. SAGE (Serial Analysis of
Gene expression) analysis further suggests that TACC3
and TACC1 are downregulated in ovarian tumors and
ovarian cancer cell lines [6]. Thus, based upon both the
location of TACC1 and TACC3 in regions consistently
associated with ovarian cancer [3,5] and SAGE expression
data [6], we have set out to determine the occurrence of
alterations of these TACCs in ovarian cancer.
Methods
Serial Analysis of Gene Expression (SAGE)
The results of SAGE analysis of libraries generated by the
method of Velculescu et al [7] were downloaded from the
SAGEMAP section of the Gene Expression Omnibus web-
site at the National Center for Biotechnology Information
[6], and critically assessed for reliability to specifically pre-
dict expression of TACC3 and TACC1 in ovarian tissue
and tumors. SAGE profiles used for TACC3 and TACC1
were [8] and [9], respectively.
Tissue and tumor microarrays
T-BO-1 and IMH-343 tissue and tumor microarray slides
were obtained from the Cooperative Human Tissue Net-
work, Tissue Array Research Program (TARP) of the
National Cancer Institute, National Institutes of Health
(Bethesda, MD, USA) and Imgenex Corporation (San
Diego, CA, USA), respectively. Each of these microarrays
contain normal tissues that are known to express TACC1
and TACC3 [10-12]. Clear cell carcinomas on the tissue/
tumor slides, which cannot be graded using the World
Health Organisation or FIGO systems [13], were classified
as grade 3, as recommended by the NCCN practice guide-
lines [14].
Immunohistochemical staining
Immunohistochemical procedures were first optimized
using formalin-fixed, paraffin-embedded MCF7 and HT-
29 cell lines prepared in our laboratory. Conditions were
then further optimized using mixed normal/tumor
human tissue microarrays (Imgenex Corporation).
Tumor microarrays were deparaffinized in three changes
of xylene and rehydrated using graded alcohols at room
temperature. Endogenous peroxidase was quenched with
aqueous 3% H2O2 for 20 min. and washed with PBS-
Tween20 (PBS/T). Antigen retrieval was performed with
citrate buffer pH 6.0 by heating twice in a microwave for
10 min., and then cooling to room temperature for 15
min. Following a PBS/T wash, the slides were placed in a
humidity chamber and 0.03% w/v casein in PBS/T was
applied to the tissue sections for 30 min. to block non-
specific binding. This was then replaced with the primary
anti-TACC3 antibody (#sc5885, Santa Cruz Biotech.,
Santa Cruz, CA, USA) at 1 µg/ml and left overnight at 4°C.
As a negative control, a duplicate slide was incubated with
antibody that had been precompeted with 10-fold excess
of TACC3 peptide competitor [Santa Cruz #sc5885P] for
2 hr. at room temperature prior to use. The slides were
then washed with PBS/T, followed by the biotinylated sec-
ondary antibody [Santa Cruz #sc2042 Donkey anti-goat]
for 30 min. A PBS/T wash was followed by incubation
with streptavidin-peroxidase reagent [#50-242, Zymed,
Carlsbad, CA, USA] for 30 min. PBS/T was used as a wash
and then chromogen DAB [#K3466, DAKO, Carpinteria,
CA, USA] was applied for 5 min. (color reaction product
– brown). The slides were then counterstained with
Hematoxylin (blue in figures), dehydrated, cleared and
finally coverslipped.
Antigen retrieval for TACC1 was essentially as described
above. Slides were then incubated overnight at 4°C with
primary anti-TACC1 antibody (#07-229, Upstate, Lake
Placid, NY, USA) at 1 µg/ml. Concentration matched rab-
bit IgG (1 µg/ml) was used on a duplicate slide, instead of
the primary TACC1 antibody, as a negative control for
immunostaining. The slides were then placed on a DAKO
autostainer with the following program; 1) one PBS/T
wash; 2) incubation with a biotinylated secondary anti-
body [Vector Elite kit] for 30 min.; 3) one PBS/T wash;
and then 4) incubation with ABC reagent [Vector Elite kit]
for 30 min. PBS/T was used as a final wash and chro-
mogen-DAB [DAKO] was applied for 5 min. (color reac-
tion product – brown). The slides were then
counterstained with Hematoxylin and dehydrated,
cleared and coverslipped.BMC Women's Health 2005, 5:8 http://www.biomedcentral.com/1472-6874/5/8
Page 3 of 10
(page number not for citation purposes)
Image analysis
Tumor microarrays were examined by light microscopy
and cores were categorized into either positive (+) or neg-
ative (-) staining for TACC3 and TACC1, with (+) staining
representing those cores where greater than 10% of the
cells had detectable staining, otherwise they were scored (-
). No staining was observed in the negative controls,
which were serial tumor microarray slides that were incu-
bated with either peptide block or IgG depending upon
the test antibody. Positive controls were normal tissues on
each tissue and tumor array, and normal ovarian surface
epithelium. Images were captured using a Nikon eclipse
E600 microscope with Spot insight digital camera and
Spot Advanced software version 4.0.1 (Diagnostic Instru-
ments, MI, USA).
Statistical analysis
Fisher's exact test was performed using GraphPad Prism
Version 3.03, (GraphPad Software, San Diego, California,
USA, http://www.graphpad.com). All tests were two-sided
and p < 0.05 and p < 0.02 were considered to be signifi-
cant for single and multiple comparisons respectively.
Mutation analysis using Transgenomic WAVE dHPLC
The TACC3 gene was screened for mutations using the
Transgenomic WAVE dHPLC system [15]. The sequence of
each fragment to be amplified by the polymerase chain
reaction (PCR) was first analyzed using the WAVE melting
profile software program to determine gradient and col-
umn temperature conditions for each PCR product. Indi-
vidual exons and intronic regions encompassing the 5'
and 3' splice sites were then amplified from a standard
commercial normal human placental DNA sample (con-
ditions and primer sequences available on request). These
PCR products were then used to establish the actual melt-
ing profiles for each exon. Test samples were mixed with
the standard normal control PCR product at a 1:1 ratio
and denatured at 95°C for 5 min., followed by slow cool-
ing to room temperature at the rate of 0.1°C every four
seconds to enhance heteroduplex formation. WAVE
dHPLC analysis was then performed and patterns com-
pared with matched normal sibling controls (non-symp-
tomatic) and the unmixed normal control pattern. For all
variant patterns detected, aliquots from the original PCR
reaction were then directly sequenced by the Roswell Park
Cancer Institute Biopolymer core facility. Variant
sequences were cross-referenced against GenBANK and
Single Nucleotide Polymorphism databases [16], to test
for occurrence in a wider population sample. New gene
alterations that were found only in cDNAs from normal
tissues in the databases, or found in normal and affected
individuals in our test subjects were labelled as
polymorphisms.
All investigations were performed after approval by the
Roswell Park Cancer Institute institutional review board.
Results
Expression analysis of TACC1 and TACC3 in ovarian 
tumors
TACC1 and TACC3 are expressed in the epithelia of a
number of different tissues, including the mammary
gland and the ovary [17-19] (Fig. 1), suggesting that these
proteins may be required for the normal maintenance of
the epithelial component of organs within the body. Pub-
lished SAGE (Serial Analysis of Gene Expression) analysis
suggests that TACC1 expression is absent in 3 out of 7
bulk ovarian tumors and cell lines (Figure 3). Further-
more, TACC3 is downregulated in all 7 of the bulk ovarian
tumors and tumor cell lines, compared with the normal
human ovarian surface epithelium (HOSE) (Figure 3) [6].
Notably, similar to the two transciption factors GATA4
and GATA6 [20], TACC3 downregulation occurs in
IOSE29, an immortalized ovarian surface epithelial cell
line, suggesting that loss of TACC3 expression may be an
early event during the immortalization process. To deter-
mine whether the pattern of gene expression noted by
SAGE analysis is also evident in patient tumors, we
assessed ovarian tumor microarrays from the National
Cancer Institute multi-tumor tissue microarray (TARP)
facility for expression of both proteins. 65 of the 75 OSE
tumors on the tissue/tumor microarray could be evalu-
ated for both TACC1 and TACC3 expression after the
immunostaining procedure. Representative images dem-
onstrating positive or negative tumor staining compared
to normal human ovarian surface epithelium are shown
in Fig. 1. A total of 21 (32.3%) and 41 (63.1%) showed
positive staining for TACC3 and TACC1 respectively
(Table 1). Thus, 44 (67.7%) and 24 (36.9%) could be cat-
egorized as absent or minimal expression for TACC3 and
TACC1 respectively, similar to the results observed in the
SAGE analysis. In addition, the allocation of TACC1 and
TACC3 status to each core showed that 78.5% of the
tumors exhibited negative immunoreactivity for one or
both proteins. Within the ovarian tumor set tested (n =
65), there was a significant difference in the expression of
TACC1 compared to TACC3 (Fisher's exact test, p =
0.0008) (Fig. 2). Expression of neither protein was associ-
ated with tumor grade. In all cases where TACC3 expres-
sion was observed, the protein was excluded from the
nucleus (Fig. 1), contrary to the predominantly nuclear
localization observed in the normal ovarian surface epi-
thelium in vivo [17-19] (Fig 1). These results indicate that
tumors derived from the ovarian surface epithelium
exhibit low/negative expression or aberrant localization
of TACC3, which may biologically contribute to develop-
ment of these tumors.BMC Women's Health 2005, 5:8 http://www.biomedcentral.com/1472-6874/5/8
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Next, we examined the association of expression of each
TACC protein with specific types of tumor to test whether
the distribution of each TACC varied between subtypes
(Summarized in Table 1). TACC3 expression was
observed in 21.4% (9 of 42) serous papillary, 40% (2 of
5) mucinous, 42.8% (3 of 7) endometroid, and 63.6% (7
of 11) clear cell ovarian tumor cores. A significant differ-
ence in TACC3 expression between tumor types was
noted, with TACC3 being expressed less frequently in
serous papillary tumors than clear cell tumors (Fisher's
exact test, p = 0.0113). In contrast, TACC1 was detected in
71.4% (30 of 42) serous papillary, 60% (3 of 5) muci-
nous, 28.6% (2 of 7) endometroid and 54.5% (6 of 11)
clear cell ovarian tumor cores. TACC1 expression was less
frequent in endometroid than in serous papillary tumors
(Fisher's exact test p = 0.0406). Noticeably, TACC3 com-
pared with TACC1 staining in serous papillary tumors was
significantly different (Fisher's exact test, p < 0.0001) (Fig.
2). There was no significant difference between their
expression in clear cell, endometroid or mucinous tumor
types. However, as it is more difficult to obtain large num-
bers of these less common types of ovarian cancer, it
should be stressed that further analysis will be required to
investigate whether relationships between tumor type and
grade will hold in a larger sample set.
Mutation analysis of the TACC3 gene in familial ovarian 
cancer
The prevalence of structural aberrations in 4p16 noted
during ovarian tumorigenesis indicates that this region
could contain one or more genes whose normal role is to
control the growth and maintenance of the ovarian sur-
face epithelium [3-5]. Thus, loss of one copy of 4p16 in
the developing ovarian tumor may result in haploinsuffi-
ciency, or unmask a pathogenic mutation in one or more
of the genes in this region. With the evidence from the
expression analysis presented above, it would appear that
a significant number of ovarian cancers lack TACC3
Immunohistochemical analysis of tumor micoarrays Figure 1
Immunohistochemical analysis of tumor micoarrays. Representative normal human ovarian surface epithelium and 
tumor cores stained for TACC1 (panels A-E), and TACC3 (panels F-J) proteins to show positive and negative staining. TACC 
protein expression is detected as a brown signal against the blue Hematoxylin counterstain. In all cases where TACC3 expres-
sion was observed, the protein was excluded from the nucleus of the ovarian tumor cells, unlike the observable nuclear and 
cytoplasmic expression of TACC1. A, normal ovarian surface epithelium with nuclear/cytoplasmic TACC1 staining; B, serous 
papillary TACC1 +ve; C, serous papillary TACC1 -ve; D, endometroid TACC1 +ve; E, endometroid TACC1 -ve; F, normal 
ovarian surface epithelium with nuclear TACC3 staining; G, serous papillary TACC3 +ve; H, serous papillary TACC3 -ve; I, 
clear cell TACC3 +ve; J, clear cell TACC3 -ve. A-H: Main panel original magnification ×40; insets show whole tumor core at 
original magnification ×10.BMC Women's Health 2005, 5:8 http://www.biomedcentral.com/1472-6874/5/8
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expression. As the TACC3 gene is located within 4p16
[11], we next investigated whether constitutional muta-
tions occur within the TACC3 gene in familial ovarian
cancer. Thus, mutation analysis was performed on the
TACC3 coding sequence, and the corresponding intron/
exon boundaries of this 16 exon gene. Specifically, we
used the Transgenomics WAVE dHPLC technology as a
pre-screening approach to sample constitutional DNA
from ovarian cancer patients and their unaffected relatives
from 76 families from the Gilda Radner Familial Ovarian
Cancer Registry. These families had previously tested neg-
ative for mutations in known ovarian cancer predisposi-
tion genes, including BRCA1 and BRCA2, and thus the
underlying genetic predisposition in these families is cur-
rently unknown [2].
We identified novel sequence variants in a number of the
samples, but most of these were due to polymorphisms in
the intronic sequence included in the amplified products.
However, novel sequence substitutions were also identi-
fied in the TACC3 coding sequence (Table 2), many of
which resulted in no change at the protein level. Four
nucleotide substitutions, not found in the GenBANK or
SNP databases, which did alter the protein sequence were
identified in both normal and affected sibs and thus also
categorized as novel polymorphisms. In most cases, the
alterations resulted from C to T base changes in CpG dinu-
cleotides. Intriguingly, we identified a relatively rare inser-
tion/deletion polymorphism in two 12mer amino acid
repeats encoded by exon four [11]. The identification of
this polymorphism could explain the previously reported
variable number of copies of a distinct 24 amino acid
repeat found in mouse TACC3 cDNAs from various
sources [11,18,21]; although in only one case was the cor-
responding exon (exon 4) sequenced [18].
Significantly, in two unrelated patients from different
families, we identified sequence alterations that were not
present in unaffected sib(s) in the respective families or
unrelated samples. In one case, a heterozygous C to T
mutation in exon 6 was detected in the affected sister, but
not her unaffected sister or sibling (Table 2). This muta-
tion results in the dramatic change of amino acid 514
from glycine to negatively charged glutamic acid, and was
not identified in any other normal or affected individuals
from the registry, so far tested. Cross-referencing this
sequence to GenBANK revealed only five occurrences of
this mutation in cDNAs from the Expressed Sequence Tag
database, all of which were derived from tumor tissues
(including brain tumors and leukemias). The underlying
c.1541G>A nucleotide substitution was detected in the
SNP database from a survey of 71 individuals (subdivided
into three panels based upon ethnicity), with the minor A
allele frequency ranging from 0.312 in the Caucasian
North American panel to 0.109 in the African American
panel, frequencies that are higher than our detection of
this allele in the Gilda Radner registry i.e. in one affected
individual in the 76 families tested. In the second family,
a heterozygous constitutional mutation was detected in
exon 3 that resulted in a serine-leucine change at amino
acid 93 in a patient diagnosed with clear cell ovarian car-
cinoma. This sequence change was not identified in other
individuals from the registry, or in the GenBANK and SNP
databases. The mother of this patient was previously diag-
nosed with uterine cancer (although the exact subtype of
tumor was not recorded), and was also heterozygous for
the same mutation. Two sisters, who are currently disease-
free, do not carry the mutation. These data suggest that
TACC3 may be a new familial predisposition or modifier
locus for gynecological cancer.
Discussion
TACC1 and TACC3 are expressed in the epithelial compo-
nents of several tissues in the body, including the mam-
mary gland and the ovary. Based upon inferences from
current SAGE data and accumulating genomic analysis,
the specific goal of this report was to determine the poten-
tial significance of these proteins in the development of
ovarian cancer. This has revealed that 78.5% of ovarian
tumors lack appreciable expression of TACC1 and/or
TACC3. In particular, we have determined that 67.7% (44
Summary chart of the expression of TACC1 and TACC3 rel- ative to ovarian tumor type Figure 2
Summary chart of the expression of TACC1 and 
TACC3 relative to ovarian tumor type. The difference 
between expression of TACC3 and TACC1 in all types of 
tumors, and the serous papillary subtype in particular, was 
significant (Fisher's exact test, p = 0.0008, and p < 0.0001 
respectively).BMC Women's Health 2005, 5:8 http://www.biomedcentral.com/1472-6874/5/8
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Serial Analysis of Gene Expression for TACC1 and TACC3 in ovarian cancer Figure 3
Serial Analysis of Gene Expression for TACC1 and TACC3 in ovarian cancer.
Table 1: Distribution of TACC1 and TACC3 expression in ovarian tumors
Tumor type TACC3a TACC1a TACC3 & TACC1b
Tumor gradesc Tumor gradesc Tumor gradesc
I II III all I II III all all
serous papillary 1d (7)e 14.3%f 6 (18) 33.3% 2 (17) 11.8% 9 (42) 21.4% 6 (7) 85.7% 13 (18) 72.2% 11 (17) 64.7% 30 (42) 71.4% 6 (42) 14.3%
mucinous 1 (3) 33.3% 0 (1) 0% 1 (1) 100% 2 (5) 40% 1 (3) 33.3% 1 (1) 100% 1 (1) 100% 3 (5) 60% 2 (5) 40%
endometroid 3 (5) 60% 0 (1) 0% 0 (1) 0% 3 (7) 42.8% 2 (5) 40% 0 (1) 0% 0 (1) 0% 2 (7) 28.6% 1 (7) 14.3%
clear cellg 7(11) 63.6% 7 (11) 63.6% 6 (11) 54.5% 6 (11) 54.5% 5 (11) 45.5%
all types 5 (15) 33.3% 6 (20) 30.0% 10 (30) 33.3% 21(65) 32.3% 9 (15) 60.0% 14 (20) 70.0% 18 (30) 60.0% 41 (65) 63.1% 14 (65) 21.5%
aExpression irrespective of the status of the other TACC protein;
bTumor cores expressing both proteins;
cSixty five cores could be graded (1,2,3) and scored for TACC1 and TACC3 expression. Tumors with less than 10% of cells stained were classed as 
negative (-), greater than 10%, as positive (+). Percentage expression was calculated within each histological subtype.
dNumber of positive cores in a set;
eTotal number of cores in a set;
fPercentage of positive cores in a set;
gClear cell carcinomas cannot be graded using the World Health Organisation or FIGO systems [13], but are classified as grade 3, as recommended 
by the NCCN practice guidelines [14].
SAGE Library source tissue/cell line SAGE Library Relative expression level
a
TACC3 TACC1
Human ovarian surface epithelium SAGE HOSE 4
IOSE29 ovarian surface epithelium cell line SAGE IOSE29 11
Bulk ovarian serous adenocarcinoma SAGE OVT-6
Bulk ovarian serous adenocarcinoma SAGE OVT-7
b
Bulk ovarian serous adenocarcinoma SAGE OVT-8
Ovarian serous adenocarcinoma cell line SAGE ES2-1
Bulk ovarian tumor SAGE OC14
b
Ovarian serous adenocarcinoma cell line SAGE A2780-9
b
ML10-10 ovarian cystadenoma cell line SAGE ML10 10
a Relative expression levels are shown as a "dosimetric" representation of the number of SAGE tags for the target gene
per million tags in the SAGE library.
bAbsentBMC Women's Health 2005, 5:8 http://www.biomedcentral.com/1472-6874/5/8
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of 65) of ovarian tumors lose expression of TACC3.
Subdivision of the tumors suggested a difference in the
distribution pattern of expression of the two TACC pro-
teins, with TACC3 loss being more common in serous
papillary carcinoma compared with clear cell carcinomas,
while TACC1 staining was less frequent in endometroid
than in serous papillary tumor cores. However, due to the
relatively small numbers of tumors in each histological
category, particularly the rarer endometroid and muci-
nous subtypes, firm conclusions about the exact distribu-
tion pattern will require analysis of a much larger sample
set. Furthermore, we detected constitutional mutations in
the TACC3 gene in ovarian cancer patients from the Gilda
Radner Familial Ovarian Cancer registry, in the absence of
mutations in known predisposition genes.
During growth and progression, tumors can undergo a
substantial amount of genomic rearrangement, including
translocations, deletions and amplifications. Although
many of these changes are random, due to the inherent
genomic instability that can occur during tumor cell divi-
sion, consistent abnormalities in the same or related
tumor types can suggest that one or more genes in a par-
ticular region may be involved in the pathogenesis of the
disease. Several different cancers, and in particular, breast,
ovarian, endometrial and cervical cancers exhibit loss of
4p16 [5,22-27], the site of the TACC3 gene [11,10]. Thus,
if TACC3 were a significant player in the pathogenesis of
cancer, we would expect that a proportion of these tumors
could similarly lose expression of TACC3. Indeed, in a sur-
vey of 500 resected breast tumors, TACC3 protein was
significantly reduced in approximately 50% of the tumors
[28]. In contrast, Affymetrix microarray analysis has
revealed that levels of TACC3 mRNA increase during the
transition of breast cancer from preinvasive ductal carci-
noma in situ to invasive ductal carcinoma [29], suggesting
that TACC3 may impart a proliferative advantage to a sub-
set of breast cancers. A more recent study has indicated
that TACC2 and TACC3 are members of a set of 21 pro-
teins that are strong prognostic indicators of clinical out-
come in breast cancer [30]. In addition, TACC3 is located
within 200 kb of a translocation breakpoint cluster region
associated with multiple myeloma, which results in
TACC3 upregulation. This suggests that an increase in
TACC3 may contribute to the pathogenesis of this B-Cell
disorder [11]. A similar dichotomy in the expression pat-
tern of TACC1 has been observed, in that TACC1 can be
upregulated or lost in cancer [28,31,32]. This may in part
be explained by as yet unidentified tissue specific func-
tions of these proteins or the existence of cancer-associ-
ated alternative splice products, as evidenced for TACC1
in gastric cancer [32]. However, currently there is no firm
evidence for alternative splicing of TACC3 in normal or
cancerous tissues.
Each human TACC gene maps to a region of the genome
that is consistently associated with tumorigenesis and pro-
gression. Rearrangements of the short arm of chromo-
some 8 are noted in several different cancers [3,33-35].
Typically, these rearrangements span a significant portion
of 8p21-8p11, encompassing the TACC1 locus. Similarly,
loss of chromosome 10, in particular the region of chro-
mosome 10q25-26 flanked by the DNA markers D10S221
to D10S216, which encompasses the TACC2 locus, is a
frequent occurrence in cancers of different origins
(Reviewed in [36]). While this could suggest that the
Table 2: TACC3 sequence changes detected in members of the Gilda Radner registry
Exon Codon Change Nucleotide changea Effectb Change in amino acid/protein 
property
Remarks
3 TCA>TTA c.278C>T Ser93Leu Hydrophilic to hydrophobic In proband (ovarian cancer), and mother 
(uterine cancer); not in two unaffected sisters.
4 GAG> AAG c.427G>A Glu143Lys Acidic to basic Polymorphism
4 AGC>AGT c.531C>T Ser177Ser Silent Polymorphism
4 c.673_708del
AAAGCGGAGACTCCGCACG
GAGCCGAGGAAGAATGC
Lys225_Cys236del Removal of one 12 amino acid 
repeat
Polymorphism
4 GGC>GGG c.1086C>G Gly362Gly Silent Polymorphism
4 Ccg>Ctg c.1250C>T Pro417Leu Potential tertiary structure 
change
Polymorphism
5 GCG>GTG c.1406C>T Ala469Val Polymorphism
6 GGG>GAG c.1541G>A Gly514Glu Small hydrophobic to acidic Only in affected sibling, not in unaffected sister 
or daughter.
9 TTC>TTT c.1809T>C Phe603Leu Aromatic to aliphatic Polymorphism
11 CAC>CAT c.1998C>T His666His Silent Polymorphism
16 c.2621T>A 3' untranslated region. Polymorphism
a: Based upon RefSeq TACC3 nucleotide sequence NM_006342
b: Based upon RefSeq TACC3 Protein sequence NP_006333BMC Women's Health 2005, 5:8 http://www.biomedcentral.com/1472-6874/5/8
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TACC genes may be mutated in a proportion of these can-
cers, to our knowledge, no report has directly assessed this
possibility. With the prevalence of aberrations in the
expression of TACC3 in the ovarian tumor arrays, we
screened the coding sequence of the TACC3 gene in 76
ovarian cancer families that do not have mutations in
known ovarian predisposition loci, such as BRCA1 and
BRCA2 [1,2]. This led to the identification of several new
coding polymorphisms, which were found in normal and
affected individuals in our test subjects. With the relatively
late age of onset of ovarian cancer, it remains possible that
some of the siblings that have been classified as normal
may actually be asymptomatic carriers. Thus, some of
these novel polymorphisms may actually represent low
penetrance modifiers of ovarian cancer risk, in a similar
manner to BARD1 polymorphisms that were subse-
quently shown to be associated with increased breast can-
cer risk in the general population [37-39].
In addition, we identified two germline constitutional
missense mutations that were specific to the affected
patient, and were not found in currently unaffected sib-
lings or unaffected members of the Gilda Radner registry.
In addition, the Ser93Leu substitution was not found in
normal individuals or cDNAs from the SNP or GenBANK
databases. Significantly, the mother of the patient that car-
ried the Ser93Leu substitution was also heterozygous for
the same mutation and had previously been treated for a
uterine cancer of undetermined type, while two siblings
without this mutation remain disease free to date. In the
Gilda Radner registry, the risk for uterine cancer is
approximately five fold higher than the general popula-
tion, and this risk increases with the number of first degree
relatives diagnosed with ovarian cancer [40]. A similar
finding was observed in a separate genealogy-based study
[41]. Indeed, a link between ovarian and uterine cancer
may not be surprising given the common embryonic ori-
gin of the epithelium of the female reproductive tract i.e.
the coelomic epithelium [42]. In an independent study, in
one BRCA1 linked family, the daughter of a patient diag-
nosed with ovarian cancer not only had bilateral breast
cancer, but also uterine leiomyomata [43,44]. In addition,
a germ line missense mutation in the BRCA1 associated
protein BARD1 can give rise to independent tumors in the
breast, ovary (clear cell carcinoma) and endometrium
(also a clear cell carcinoma) [37]. This connection is par-
ticularly intriguing considering the recent observation
that the C. elegans TAC protein interacts directly with the
C. elegans homologue of BARD1 [45]. Unfortunately, we
were unable to obtain additional tumor samples from our
patients or material from an additional affected family
member for further study. The Gly514Glu mutation,
noted in the second family, is also present in five cDNAs
derived from cancer cell lines or tumors in the expressed
sequence tag (EST) database. Interestingly, the TACC3
sequence cloned by McKeveney et al [21] also contains the
Gly514Glu substitution. Once again, this sequence was
derived from a leukemia cell line, not from a normal tis-
sue counterpart, suggesting that mutations in TACC3 may
also be a feature of other hematological malignancies, in
addition to the previously documented aberrant expres-
sion observed in multiple myeloma [46]. Intriguingly,
two previous studies have reported an increased risk of
ovarian cancer in the daughters of mothers with multiple
myeloma [47,48], raising the possibility that TACC3 is a
candidate gene contributing to the familial association of
these two diseases. Further, larger population studies will
be required to confirm whether both these changes repre-
sent rare polymorphisms, low penetrance modifiers that
contribute to ovarian cancer development and/or are
direct pathological mutations.
Potential functional significance of alterations of TACC3 
in the ovarian surface epithelium
The TACC genes were first identified as potential onco-
genes and tumor suppressors in breast cancer [10,36,49].
However, it is apparent from their proposed functions in
cell division, transcriptional and posttranscriptional con-
trol, that they have the potential to interact with pathways
that are commonly mutated in several different forms of
cancer. TACC3 has an evolutionarily conserved interac-
tion with the microtubule associated proteins and mitotic
regulators, chTOG [50], and Aurora A kinase, and can be
phosphorylated by the latter (Reviewed in [51]). In addi-
tion, a genetic interaction between TACC3 and p53 has
been suggested, based upon work carried out in mice [52].
Intriguingly, we have recently found that TACC3 associ-
ates with a BRCA1-containing complex (Lauffart et al
unpublished), and Boulton et al [45] have shown that C.
elegans TAC directly interacts with the C. elegans homo-
logue of BARD1. These functional interactions suggest
that loss of the TACC proteins may promote tumor pro-
gression by increasing aberrations in centrosomal dupli-
cation and function, or DNA damage responses [10,53].
In addition, TACC3 has been shown to interact with
nuclear localized transcription factors [18,51,54] and his-
tone acetyltransferases [55]. Overexpression of TACC3 in
hematopoietic cells results in aberrant localization of
FOG1 [54], a regulator of the GATA transcription factors.
Intriguingly, similar to TACC3, two members of this latter
family, GATA 4 and GATA 6, are either lost or mislocal-
ized in ovarian tumors [20]. Given the potential ability of
TACC3 to interact with proteins known to be involved in
ovarian tumorigenesis, our data therefore raise the possi-
bility that TACC3 mutation, mislocalization or loss may
serve as alternative mechanisms of functional inactivation
of GATA4/6 and BRCA1 leading to the dedifferentiation
and malignant development of the ovarian surface
epithelium.BMC Women's Health 2005, 5:8 http://www.biomedcentral.com/1472-6874/5/8
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Conclusion
This report documents the first recorded analysis of the
TACC genes during the development of ovarian cancer.
We have now shown that 78.5% of ovarian tumors lack
appreciable expression of TACC1 and/or TACC3 proteins,
confirming the inferences made from published SAGE
analysis. Together with the novel finding that constitu-
tional mutations in the TACC3 gene may be associated
with a subset of familial ovarian/gynecological malignan-
cies, this study, therefore, suggests that the TACCs, and
TACC3 in particular, are intimately involved in the mech-
anisms leading to the development of ovarian cancer.
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